Scynexis posts results for terminated Phase 3 MARIO trial in invasive candidiasis

Scynexis, Inc. had a registry update on its Phase 3 candidemia and invasive candidiasis trial known as MARIO.

• MARIO (NCT05178862) is a Phase 3 study testing IV echinocandin followed by either oral ibrexafungerp or oral fluconazole in patients with candidemia and/or invasive candidiasis, sponsored by Scynexis, Inc. This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis including candidemia.¹ The study was terminated, with the stated reason being a strategic decision not related to safety or efficacy concerns for Ibrexafungerp.¹ The trial enrolled 68 participants¹ and results were first posted on 2026-08-10, with primary completion recorded as 2025-11-07 and study completion as 2025-12-16. Posted data for the primary outcome show 28 participants in the IV echinocandin followed by oral ibrexafungerp arm and 28 in the IV echinocandin followed by oral fluconazole or best available therapy arm¹ assessed for all-cause mortality at Day 30.